CLL Society
WHAT’S NEW
Your connection to the most current news, information, and data about Chronic Lymphocytic Leukemia.
We suggest you BOOKMARK this page and visit it often. All content was current as of the date it was published.
In science and in medicine, information is constantly changing. Published content may become out-of-date as new information and data emerge.
Living with CLL
Sharing the CLL Experience: The Role of Reflection and Support
Dr. Ratner offers his memories through the lens of a physician with CLL who specializes in the care of older adults and as a Support Group facilitator.
Cancer, CLL, and Mindfulness
When diagnosed with chronic lymphocytic leukemia (CLL), doctors should pause and help patients understand the watch and wait period.
Rebranding Watch and Wait
When diagnosed with chronic lymphocytic leukemia (CLL), doctors should pause and help patients understand the watch and wait period.
Pointers on Doing Your Own CLL Research
The goal of the CLL Treatment Decision Tool is to increase your understanding of your chronic lymphocytic leukemia (CLL) and your treatment options.
I Missed It by That Much: CR but No uMRD by 1 per Million
Testing for measurable residual disease (MRD) through next-generation sequencing (NGS) with clonoSEQ revealed zero to one cell per million in the blood.
Dr. Ratner offers his memories through the lens of a physician with CLL who specializes in the care of older adults and as a Support Group facilitator.
WHAT'S NEW IN CLL / SLL
Ambassador Program for Chronic Lymphocytic Leukemia (CLL) Patients
For those living with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL / SLL), there are a number of treatment options to choose from. When it comes to time to treat, peer-to-peer dialogue can be a highly valuable form of learning and reminds us that we are not alone in this journey.
If you are living with CLL / SLL and considering various treatment options, CLL Society’s Ambassador Program can connect you with a fellow CLL patient who has received the treatment.
ADVOCACY AND POLICY
CLL Society Joins Growing Number of Groups Calling for Patient Protections from Medicare Part D Plan Utilization Management Under New IRA Kickoff
CLL Society joins 70+ groups urging CMS to protect CLL patients from Medicare Part D delays in medication access.
Advocating for Patients: CLL Society Participates in CMS Roundtable on Treatment Options
CLL Society and several CLL / SLL patients participated in a Centers for Medicare & Medicaid Services (CMS) Roundtable on Calquence.
CLL Society Joins Over 70 Patient Organizations in Support of Legislation Eliminating Barriers to Treatment
CLL Society joined All Copays Count Coalition in supporting the Help Ensure Lower Patient Copays Act to reduce barriers to treatment for chronic illness.
UPCOMING EVENTS
Wednesday, July 16, 2025 at 12:30 PM PT / 3:30 PM ET
Join CLL Society and Dr. Jennifer R. Brown for the webinar Next-Generation CLL Treatments: Understanding Clinical Trials and Future Therapeutic Strategies. This webinar will delve into the latest advancements in CLL treatment, focusing on emerging therapies currently under investigation in clinical trials. Drawing from her extensive knowledge and clinical experience, she will provide an overview of novel treatment strategies, including combination therapies, and discuss their potential impact on patient outcomes for first line and relapsed refractory options. Attendees will gain a comprehensive understanding of the current CLL treatment landscape, insights into ongoing clinical trials, and the future direction of CLL therapy. This webinar is essential for people seeking to stay informed about cutting-edge developments in CLL management and a better understanding of the clinical trial process.
This webinar and discussion will be slightly advanced, but we invite everyone to join and learn.
On-Demand Replay
If you missed the recent Q&A-style Facebook Live event “Ask Me Anything” with Dr. Lindsey Roeker and patient advocate Jeff Folloder, you can catch the replay here!
If you missed the recent webinar with Deborah Stephens, DO, and Larry Marion on Navigating CLL with a Comprehensive Wellness Approach, catch the replay, presentation slides, and transcript here! Watch now!
Treatment Updates
Statin Use Improves Outcome in CLL / SLL Patients
Several studies have shown that statin use is associated with improved outcomes in CLL / SLL patients regardless of their CLL therapy.
Zanubrutinib with del(17p) in treatment-naive CLL / SLL
Zanubrutinib, a newer BTK inhibitor, showed 60-month progression-free survival (PFS) in frontline high-risk CLL / SLL patients with del(17p)
Zanubrutinib plus Venetoclax for Frontline CLL / SLL
Combining zanubrutinib with venetoclax results in nearly a 100% response rate in frontline CLL / SLL patients.
Equitable Access and Regulatory News
EU Approves Acalabrutinib-Based Combinations for CLL
The EU commission has approved acalabrutinib in combination with venetoclax, with or without obinutuzumab, for the frontline treatment of CLL.
Understanding NCCN Guidelines for CLL / SLL as a Patient
NCCN guidelines are the gold standard where CLL experts recommend best practices. Learn what CLL patients should know about the latest update.
U.S. Government to Help Patients Access Paxlovid in 2025
The U.S. Government Patient Assistance Program will continue to help individuals access Paxlovid for the treatment of COVID-19.
